An Act to Require Health Insurance Coverage for Federally Approved Nonprescription Oral Hormonal Contraceptives and Nonprescription Emergency Contraceptives
Summary
LD 163 requires most Maine health insurance policies and contracts that already cover prescription drugs or outpatient medical services to also cover federally approved nonprescription oral hormonal contraceptives and nonprescription emergency contraceptives. The bill amends multiple insurance statutes covering health plans, nonprofit health service plans, health maintenance organizations, and other limited-benefit policies so that these products are treated like other covered contraceptive supplies when approved by the FDA.
The bill specifies that coverage must be provided without deductibles, coinsurance, copayments, or other cost-sharing. It also allows coverage for a 12-month supply, states that a prescription is not required for the nonprescription products, and requires insurers and nonprofit health plans to create mechanisms for pharmacy point-of-sale access or reimbursement after out-of-pocket purchase. The Superintendent of Insurance must monitor compliance, and the bill directs the bureau to adopt routine technical rules and enrollee notice requirements. The law applies to policies and contracts issued, delivered, renewed, or continued on or after January 1, 2026.
Impact
This bill expands Maine’s existing contraceptive coverage mandates to explicitly include over-the-counter oral hormonal contraceptives and emergency contraceptives approved by the FDA. It affects a broad range of insurers and health coverage arrangements, including individual and group health plans, nonprofit hospital and medical service plans, nonprofit health care plans, health maintenance organizations, Medicare supplement and other limited-benefit policies, and group health contracts. It also amends disclosure requirements so carriers must explain how enrollees can access these products at pharmacies without out-of-pocket cost at the point of sale or through reimbursement. The bill includes a General Fund and Highway Fund administrative cost for implementation.
Sentiment
The voting history suggests the bill had meaningful support but also notable opposition. The House accepted the minority ought-to-pass-as-amended report by a narrow margin, 73-69, indicating a closely divided chamber. The Senate then accepted the minority report by a wider but still significant margin, 21-13. Overall, the bill appears to have been viewed favorably by supporters of expanded contraceptive access, while opponents were substantial enough to produce a competitive floor debate and a minority report.
Contention
The main point of contention is likely the expansion of mandated insurance coverage for contraception, especially for products available without a prescription and for emergency contraception. Supporters would frame the bill as improving access, affordability, and convenience, while opponents may object to requiring coverage, the cost-sharing mandate, or the inclusion of emergency contraception. The bill also carefully states that it does not apply to drugs or devices designed to terminate a pregnancy, which suggests sensitivity to abortion-related concerns and a need to distinguish contraception from pregnancy termination in the statutory language.